Phospho-CRK(Y221) Antibody Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P46108 |
---|---|
Other Accession | Q96GA9 |
Clone Names | 110024 |
Gene ID | 1398 |
---|---|
Other Names | Adapter molecule crk, Proto-oncogene c-Crk, p38, CRK |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP3446a was selected from the region of human Phospho-CRK-Y221. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CRK |
---|---|
Function | Involved in cell branching and adhesion mediated by BCAR1- CRK-RAPGEF1 signaling and activation of RAP1. |
Cellular Location | Cytoplasm. Cell membrane. Note=Translocated to the plasma membrane upon cell adhesion. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CRK is a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. It has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation.
References
Bougneres, L., et al., J. Cell Biol. 166(2):225-235 (2004).Stoletov, K.V., et al., Exp. Cell Res. 295(1):258-268 (2004).Miller, C.T., et al., Oncogene 22(39):7950-7957 (2003).Sun, J., et al., J. Biol. Chem. 278(35):32794-32800 (2003).Zhang, X.A., et al., J. Biol. Chem. 278(29):27319-27328 (2003).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.